InflaRx falls after pricing public offering

Inflarx NV

14/02/2025 11:33

** U.S.-listed shares of German-based biopharma firm InflaRx
 IF0G.F   IFRX.O  fall 18.5% to $2.20 premarket
    ** On Thursday, co said it is raising $30 mln through public
offering
    ** Co is selling 8.25 mln shares at $2/shr; represents a
25.9% discount to the stock's last close
    ** Also selling pre-funded warrants to buy up to 6.75 mln
more shares to certain investors, which can be exercised for
$0.001/shr
    ** Co intends to use the net proceeds to develop new
medicines, including vilobelimab and INF904, and for general
company purposes
    ** Co said it may sell up to 2.25 mln more shares if the
underwriters want to buy them
    ** Co has 58.9 mln outstanding shares with a market cap of
~$159 mln - data compiled from LSEG
    ** Guggenheim Securities, LLC acting as book-running manager
for the offering
    ** Co gained 50.6% in 2024

 (Reporting by Kamal Choudhury in Bengaluru)
 ((Kamal.Choudhury@thomsonreuters.com;))